CELGENE PURCHASES IMPACT ON STRENGTH OF FEDRATINIB
MPNRF | January 9, 2018
January 9, 2018
Celgene has purchased Impact Biologics, who was reviving the drug Fedratinib. Fedratinib is a JAK2 inhibitor, and the trial end points include spleen reduction and symptom relief. Click here for more information about the deal.
Further context is provided by MPN Forum who wrote about it’s revival in their December issue.
It is also included among the topics of the post-ASH video featuring John Crispino and Angela Fleischman.
Forbes also featured the story of John Hood, who created Fedratinib.
If succesful, this would provide additional options for MPN patients who have a limited toolkit of therapies to choose from.